Study guide

Paediatric AKI (pRIFLE/KDIGO), Haemolytic Uraemic Syndrome (HUS), and Hyperkalaemia/Dysnatraemia Management

EBP-EAP Examination in Paediatrics Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Governance, Ethics & Child Safeguarding

EBP-EAP Format, Delivery, Scoring, and Clinical Vignette Strategy Paediatric Ethics, Consent/Assent, Gillick Competence, and Patient Safety Child Protection, Physical/Emotional Abuse, Neglect, and Non-Accidental Injury (NAI)

2 Chapter 2: Neonatal Transition, Resuscitation & Prematurity

Delivery Room Care, Apgar Scoring, and Neonatal Resuscitation Algorithm Respiratory Distress Syndrome (RDS), Surfactant Therapy, and Bronchopulmonary Dysplasia Perinatal Asphyxia, HIE Sarnat Staging, and Therapeutic Hypothermia Protocol

3 Chapter 3: Neonatal Morbidities, Jaundice & Congenital Infections

Unconjugated vs Conjugated Hyperbilirubinemia, Phototherapy Thresholds, and Exchange Transfusion Early- vs Late-Onset Sepsis, Group B Streptococcus, and Congenital TORCH Infections NEC Diagnosis/Bell Staging, Neonatal Hypoglycaemia, and Newborn Bloodspot Screening

4 Chapter 4: Acute Paediatric Emergencies & Critical Care

EPLS/PALS Structured Approach, Types of Shock, and Weight-Based Fluid Boluses Clinical Diagnostic Criteria, Intramuscular Adrenaline Dosing, and Refractory Anaphylaxis 5-Minute Time-Critical Anticonvulsant Protocol and Status Epilepticus Care Common Toxidromes (Paracetamol, Iron, Caustics, Button Batteries) and Decontamination

5 Chapter 5: Paediatric Respiratory Medicine

Stridor Differential, Croup (Westley Score & Dexamethasone), and Epiglottitis RSV Pathogenesis, Supportive Management, Oxygen/High-Flow Criteria, and Futility of Bronchodilators/Steroids European/BTS Guidelines on Chronic Stepwise Control and Acute Severe Exacerbation Management Community-Acquired Pneumonia Etiology, Parapneumonic Effusion/Empyema, and Cystic Fibrosis Pulmonary Exacerbations

6 Chapter 6: Paediatric Cardiology

Acyanotic vs Cyanotic Congenital Heart Disease: Ductal Patency, Shunt Lesions, and Emergency Stabilization Paediatric Murmurs and Arrhythmias: Innocent vs Pathological Murmurs, SVT, and Resuscitation Protocols Acquired Heart Disease: Kawasaki Disease, Coronary Aneurysm Prevention, and Acute Rheumatic Fever

7 Chapter 7: Paediatric Gastroenterology, Hepatology & Nutrition

Dehydration Severity Assessment, Oral Rehydration Therapy (ORT), and Intravenous Fluid Protocols ESPGHAN Coeliac Diagnostic Criteria (Biopsy-Sparing Pathway) and Paediatric Crohn's/Ulcerative Colitis Breastfeeding, Formula Selection, Cow's Milk Protein Allergy (CMPA), GERD vs GOR, and Faltering Growth Prolonged Neonatal Jaundice Workup, Biliary Atresia Red Flags, and Acute Hepatitis/Liver Failure

8 Chapter 8: Paediatric Nephrology, Fluids & Electrolyte Balance

Paediatric UTI Diagnosis, Imaging Criteria (Ultrasound/DMSA/MCUG), and Vesicoureteral Reflux Minimal Change Nephrotic Syndrome (Steroid Regimen & Complications) vs Acute Post-Infectious Glomerulonephritis Paediatric AKI (pRIFLE/KDIGO), Haemolytic Uraemic Syndrome (HUS), and Hyperkalaemia/Dysnatraemia Management

9 Chapter 9: Paediatric Endocrinology & Inborn Errors of Metabolism

Paediatric DKA Protocol (ISPAD/European Fluid & Insulin Guidelines, Cerebral Oedema Prevention) and T1DM Maintenance Congenital Hypothyroidism Screening & Levothyroxine, Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency), and Adrenal Crisis Short Stature Workup, Precocious vs Delayed Puberty, and Approach to Suspected Inborn Errors of Metabolism (IEM)

10 Chapter 10: Paediatric Neurology, Neurodevelopment & Mental Health

Simple vs Complex Febrile Seizures, Childhood Epilepsy Syndromes (Absence, Infantile Spasms, Benign Rolandic), and Antiseizure Medications Red Flags for Raised Intracranial Pressure (ICP), Brain Tumours, Migraine vs Tension Headache Acute Bacterial Meningitis (LP Contraindications, Ceftriaxone, Dexamethasone) and Viral Encephalitis (Aciclovir) Developmental Milestones (Gross Motor, Fine Motor/Vision, Speech/Language, Social), Autism Spectrum, ADHD, and Cerebral Palsy

11 Chapter 11: Paediatric Haematology & Oncology

Microcytic Anaemia (Iron Deficiency vs Thalassaemia Trait/Mentzer Index), Haemolytic Anaemias (Spherocytosis, G6PD) Sickle Cell Crises (Vaso-occlusive, Acute Chest Syndrome, Stroke Prevention), Immune Thrombocytopenia (ITP), and Haemophilia A/B Acute Lymphoblastic Leukaemia (ALL), Neuroblastoma, Wilms Tumour, and Management of Febrile Neutropenia

12 Chapter 12: Paediatric Infectious Diseases, Immunology & Allergy

Common Childhood Exanthems: Clinical Morphology, Timelines, Complications, and Management Paediatric Tuberculosis, Sepsis Six in Children, and Acute Osteoarticular Infections Pediatric Allergy, Atopic Eczema, Food Hypersensitivity, and Desensitization Primary Immunodeficiencies, Warning Signs, Live Vaccine Contraindications, and European Immunisation Schedules

13 Chapter 13: Paediatric Musculoskeletal, Dermatology & Surgical Conditions

The Limping Child, Septic Arthritis vs Transient Synovitis, and Juvenile Idiopathic Arthritis Henoch-Schönlein Purpura, Kawasaki Disease vs MIS-C, Infantile Haemangiomas, and Common Pediatric Eruptions Acute Appendicitis, Intussusception, Pyloric Stenosis, Testicular Torsion, and Incarcerated Hernia

14 Chapter 14: Research Methods, Biostatistics & Evidence-Based Paediatrics

Study Designs, Causality, Bias, and Epidemiological Measures in Paediatrics Diagnostic Test Accuracy, Statistical Inference, and Hypothesis Testing Systematic Reviews, Meta-Analysis, Decision Analysis, and Paediatric Research Ethics

15 Chapter 15: Paediatric Ophthalmology & ENT Disorders

Paediatric Vision Assessment, Refractive Disorders, Strabismus, and Leukocoria Ocular Emergencies, Orbital Infections, ROP, and Systemic Manifestations Paediatric Otolaryngology: Otitis Media, Hearing Impairment, and Upper Airway Conditions

16 Chapter 16: Paediatric Sports Medicine & Musculoskeletal Health

Skeletal Maturity, Physeal Injuries, Apophysitis, and Overuse Syndromes Paediatric Sports Concussion, Second Impact Syndrome, and Return-to-Play Protocols Pre-Participation Screening, Physical Activity Guidelines, and Chronic Disease Clearance

17 Chapter 17: Adolescent Medicine & Healthcare Transition

Biopsychosocial Development, Pubertal Staging, and Adolescent Communication Adolescent Confidentiality, Risk Behaviours, Reproductive Health, and Eating Disorders Chronic Illness in Adolescence and Structured Healthcare Transition

18 Chapter 18: Paediatric Genetics, Dysmorphology & Clinical Genomics

Patterns of Inheritance, Non-Mendelian Mechanisms, and Pedigree Construction Clinical Dysmorphology, Chromosomal Aneuploidies, and Microdeletion Syndromes Genetic Testing Technologies, Prenatal Diagnosis, and Genetic Counselling Ethics

19 Chapter 19: Paediatric Mental Health, Behaviour & Community Medicine

Cognitive Development, Attachment, Screening, and Common Emotional Disorders Regulatory Disorders, Neurodevelopmental Behavioural Conditions, and Psychosomatic Illness Community Child Healthcare Structures, Disability Coordination, and Child Advocacy

Paediatric AKI (pRIFLE/KDIGO), Haemolytic Uraemic Syndrome (HUS), and Hyperkalaemia/Dysnatraemia Management

Key Takeaways Explain This Topic AI

KDIGO and pRIFLE stage paediatric AKI using changes in kidney function and urine output. FeNa < 1 % <1\% < 1% supports prerenal physiology and > 2 % >2\% > 2% supports tubular injury, but urinary indices must be interpreted with the clinical findings and treatment history.

Haemolytic Uraemic Syndrome (HUS) is characterized by the classic diagnostic triad of Coombs-negative microangiopathic hemolytic anemia with schistocytes, thrombocytopenia, and acute kidney injury; typical D+ HUS is triggered by Shiga toxin-producing E. coli (STEC O157:H7) binding to endothelial Gb3 receptors.

Avoid antibiotics for STEC enteritis, antimotility drugs and routine prophylactic platelet transfusions. Antibiotics may be needed for another clinical indication; platelet support requires specialist assessment for life-threatening bleeding or an emergency procedure. Complement-mediated HUS requires prompt specialist C5-inhibitor treatment.

Severe hyperkalaemia needs urgent potassium shifting and removal; give IV calcium for ECG toxicity. Insulin–glucose and nebulized salbutamol provide temporary intracellular shifts. Control sodium correction: chronic hyponatraemia generally ≤ 8 – 10 mmol/L \le 8\text{--}10\text{ mmol/L} ≤ 8 – 10 mmol/L per day; hypernatraemia ≤ 0.5 mmol/L/h \le 0.5\text{ mmol/L/h} ≤ 0.5 mmol/L/h .

Last updated: November 2026

Paediatric Acute Kidney Injury, Haemolytic Uraemic Syndrome, and Electrolyte Emergencies

Acute kidney injury (AKI) and electrolyte disturbances represent frequent, high-stakes medical emergencies encountered in pediatric wards and intensive care units. Whether arising as a secondary consequence of severe dehydration, systemic sepsis, or primary microvascular insults such as Haemolytic Uraemic Syndrome (HUS), rapid recognition and pathophysiologically targeted interventions are paramount to avert permanent renal damage and cardiac arrest.

Paediatric Acute Kidney Injury: Staging and Classification

Acute kidney injury is characterized by a rapid, potentially reversible decline in glomerular filtration rate (GFR) over hours to days, resulting in the retention of nitrogenous waste products (urea, creatinine) and the dysregulation of extracellular fluid volume and electrolytes.

Pediatric Diagnostic Criteria: KDIGO vs pRIFLE

Interpreting renal function in children requires recognizing developmental physiology. In infants and children, serum creatinine reflects muscle mass ; therefore, baseline serum creatinine in a healthy infant is low ( 18 to 35 μ mol/L 18\text{ to }35\ \mu\text{mol/L} 18 to 35 μ mol/L or 0.2 – 0.4 mg/dL 0.2\text{--}0.4\text{ mg/dL} 0.2 – 0.4 mg/dL ). A creatinine of 70 μ mol/L 70\ \mu\text{mol/L} 70 μ mol/L ( 0.8 mg/dL 0.8\text{ mg/dL} 0.8 mg/dL ) may be markedly abnormal in a toddler; interpret it against baseline, age, height and the clinical course rather than assigning severity from that value alone.

Under KDIGO (Kidney Disease: Improving Global Outcomes) pediatric guidelines, AKI is defined and staged by either serum creatinine rise or oliguria:

KDIGO Stage Serum Creatinine Criteria Urine Output Criteria

Stage 1 Rise of ≥ 26.5 μ mol/L \ge 26.5\ \mu\text{mol/L} ≥ 26.5 μ mol/L ( ≥ 0.3 mg/dL \ge 0.3\text{ mg/dL} ≥ 0.3 mg/dL ) within 48 hours, OR 1.5 – 1.9 × 1.5\text{--}1.9 \times 1.5 – 1.9 × baseline within 7 days < 0.5 mL/kg/hour <0.5\text{ mL/kg/hour} < 0.5 mL/kg/hour for 6 to 12 hours

Stage 2 2.0 to 2.9 × 2.0\text{ to }2.9 \times 2.0 to 2.9 × baseline serum creatinine < 0.5 mL/kg/hour <0.5\text{ mL/kg/hour} < 0.5 mL/kg/hour for ≥ 12 \ge 12 ≥ 12 hours

Stage 3 3.0 × 3.0 \times 3.0 × baseline, OR serum creatinine ≥ 353.6 μ mol/L \ge 353.6\ \mu\text{mol/L} ≥ 353.6 μ mol/L ( ≥ 4.0 mg/dL \ge 4.0\text{ mg/dL} ≥ 4.0 mg/dL ), OR initiation of Renal Replacement Therapy (RRT), OR in patients < 18 <18 < 18 years, an acute decline in eGFR to < 35 mL/min / 1.73 m 2 <35\text{ mL/min}/1.73\text{ m}^2 < 35 mL/min /1.73 m 2 < 0.3 mL/kg/hour <0.3\text{ mL/kg/hour} < 0.3 mL/kg/hour for ≥ 24 \ge 24 ≥ 24 hours, OR anuria for ≥ 12 \ge 12 ≥ 12 hours

The pRIFLE criteria categorize dysfunction into R isk (eGFR decrease by 25%), I njury (50% decrease), F ailure (75% decrease or eGFR < 35 mL/min / 1.73 m 2 <35\text{ mL/min}/1.73\text{ m}^2 < 35 mL/min /1.73 m 2 ), L oss (persistent failure > 4 >4 > 4 weeks), and E nd-stage (ESRD > 3 >3 > 3 months).

Etiological Classification

Prerenal AKI (Functional Azotemia, ~50–60%) : Hemodynamic renal hypoperfusion with structurally intact renal parenchyma. Causes include hypovolemic dehydration (severe gastroenteritis, burns), hemorrhage, septic vasodilatory shock, cardiac pump failure, and severe third-spacing (nephrotic syndrome, liver failure).

Intrinsic Renal AKI (~30–40%) : Structural parenchymal damage:

Acute Tubular Necrosis (ATN) : Prolonged, uncorrected prerenal ischemia, or exogenous nephrotoxins (aminoglycosides, vancomycin, amphotericin B, cisplatin, intravenous radiocontrast, NSAIDs).

Vascular / Microangiopathic : Haemolytic Uraemic Syndrome (HUS), renal vein thrombosis.

Glomerular : Acute post-streptococcal glomerulonephritis, rapidly progressive glomerulonephritis (RPGN), lupus nephritis.

Acute Interstitial Nephritis (AIN) : Drug hypersensitivity (penicillins, cephalosporins, NSAIDs, proton pump inhibitors).

Postrenal AKI (Obstructive, ~5–10%) : Mechanical obstruction to urinary outflow. Congenital: Posterior Urethral Valves (PUV) in infant males, bilateral pelviureteric junction obstruction (PUJO), bilateral ureteroceles, neurogenic bladder. Acquired: Urolithiasis, tumor lysis syndrome uric acid/xanthine nephropathy, obstructing pelvic malignancy (rhabdomyosarcoma, neuroblastoma).

Differentiating Prerenal Azotemia from Acute Tubular Necrosis

The Fractional Excretion of Sodium (FeNa) measures the percentage of sodium filtered by the glomeruli that is excreted into the urine, directly evaluating tubular reabsorptive capacity:

FeNa ( % ) = U Na × P Cr P Na × U Cr × 100 \text{FeNa} (\%) = \frac{U_{\text{Na}} \times P_{\text{Cr}}}{P_{\text{Na}} \times U_{\text{Cr}}} \times 100 FeNa ( % ) = P Na ​ × U Cr ​ U Na ​ × P Cr ​ ​ × 100

Diagnostic Test Prerenal Azotemia Intrinsic Acute Tubular Necrosis (ATN) Physiological Mechanism

Fractional Excretion of Na (FeNa) < 1 % <1\% < 1% (neonates: < 2.5 % <2.5\% < 2.5% ) > 2 % >2\% > 2% In prerenal AKI, avid tubular sodium reabsorption occurs; in ATN, damaged tubules cannot reabsorb sodium

Urinary Sodium ( U Na U_{\text{Na}} U Na ​ ) < 20 mmol/L <20\text{ mmol/L} < 20 mmol/L > 40 mmol/L >40\text{ mmol/L} > 40 mmol/L Aldosterone-driven retention in prerenal states

Urinary Osmolality > 500 mOsm/kg >500\text{ mOsm/kg} > 500 mOsm/kg < 350 mOsm/kg <350\text{ mOsm/kg} < 350 mOsm/kg (Isosthenuria) Preserved medullary concentrating capacity in prerenal; lost in ATN

Urine-to-Plasma Creatinine > 40 : 1 >40:1 > 40 : 1 < 20 : 1 <20:1 < 20 : 1 Intact tubular water extraction concentrates urine creatinine

Urine Microscopy Normal, or hyaline casts "Muddy brown" granular casts , renal tubular epithelial cells Sloughed necrotic tubular cells forming pigmented casts

Note

Loop diuretics can increase FeNa and reduce its diagnostic usefulness. FeUrea below 35% may support prerenal physiology in this setting, but neither index confirms the cause of AKI independently of clinical assessment.

Haemolytic Uraemic Syndrome (HUS)

Haemolytic Uraemic Syndrome is the most common cause of intrinsic acute kidney injury in infants and young children, predominantly affecting children between 6 months and 5 years of age .

The Classic Diagnostic Triad

Microangiopathic Hemolytic Anemia (MAHA) :

Non-immune, mechanical intravascular red cell shearing across microvascular platelet thrombi.

Coombs test (Direct Antiglobulin Test, DAT) is strictly NEGATIVE .

Peripheral blood film demonstrates marked red cell fragmentation: schistocytes (helmet cells, triangular cells, burr cells) .

Marked biochemical hemolysis: Extremely elevated lactate dehydrogenase (LDH), unconjugated hyperbilirubinemia, and absent haptoglobin.

Thrombocytopenia :

Platelet count typically < 50 – 100 × 10 9 /L <50\text{--}100 \times 10^9\text{/L} < 50 – 100 × 1 0 9 /L due to consumptive trapping in endothelial microthrombi.

Coagulation Profile : Prothrombin Time (PT), activated Partial Thromboplastin Time (aPTT), and fibrinogen are NORMAL (or near-normal), distinguishing HUS from Disseminated Intravascular Coagulation (DIC).

Acute Kidney Injury (AKI) :

Ranges from microscopic hematuria and subnephrotic proteinuria to oliguric/anuric renal failure with marked azotemia and hypertension.

Typical / Enteropathic HUS (STEC-HUS / D+ HUS)

Accounts for > 90 % >90\% > 90% of pediatric HUS cases.

Etiology : Infection with Shiga toxin-producing Escherichia coli (STEC) , predominantly serotype O157:H7 (as well as O104:H4, O26, O111), and occasionally Shigella dysenteriae type 1.

Transmission : Ingestion of contaminated, undercooked beef (minced beef), unpasteurized cow's milk or fruit juices, contaminated recreational water, or direct contact with farm livestock in petting zoos.

Pathophysiological Cascade :

STEC colonizes the large bowel, producing Shiga toxins (Stx1 and Stx2) .

The toxin incites acute hemorrhagic colitis (severe abdominal cramping and copious bloody diarrhea).

Shiga toxin enters the mucosal microvasculature, travels bound to neutrophils in the systemic bloodstream, and targets vascular beds expressing the glycolipid receptor Globotriaosylceramide (Gb3) .

In the human kidney, glomerular capillary endothelial cells express exceptionally high densities of Gb3 receptors.

Toxin internalizes, cleaves 28S ribosomal RNA, arrests protein synthesis, and triggers endothelial cell apoptosis and detachment.

Subendothelial collagen exposure triggers massive localized platelet activation, localized thrombin generation, and deposition of microvascular platelet-fibrin thrombi . STEC O157:H7 Ingestion

  • |
  • Hemorrhagic Colitis (Bloody Diarrhea)
  • |
  • Shiga Toxin (Stx2) into Blood
  • |
  • Binds to Gb3 Receptors on Renal Glomerular
  • Endothelium
  • |
  • Endothelial Cell Swelling and Apoptosis
  • |
  • +----------------------+----------------------+
  • | |
  • Platelet Adhesion & Microthrombi Narrowed Glomerular Capillaries
  • | |
  • +----------------------+----------------------+
  • |
  • +-----------------+-----------------+
  • | | |
  • [Consumption] [Mechanical RBC] [Glomerular Ischemia]
  • Thrombocytopenia Shearing Acute Kidney
  • (Normal PT/aPTT) Schistocytes Injury
  • (Coombs Neg) (Oliguria/Azotemia)
  • Interventions to Avoid in Routine STEC Management

Avoid the following routine interventions in suspected or proven STEC enteritis/HUS:

Do Not Use Antibiotics to Treat STEC Enteritis :

Antibiotics may increase the risk of HUS and are not recommended for STEC infection itself. Treat another suspected serious bacterial infection when clinically indicated, with specialist advice.

ANTIMOTILITY AGENTS ARE STRICTLY CONTRAINDICATED :

Agents that slow bowel motility (e.g., Loperamide , Diphenoxylate-atropine, opioids) paralyze intestinal peristalsis. This prolongs mucosal contact time with the bacteria and toxins, dramatically increases systemic toxin absorption, and worsens both neurological complications and renal necrosis.

ROUTINE PLATELET TRANSFUSIONS ARE STRICTLY CONTRAINDICATED :

Platelet transfusions must NEVER be administered purely to correct a low laboratory platelet count , regardless of how low the number is (even < 10 × 10 9 /L <10 \times 10^9\text{/L} < 10 × 1 0 9 /L ).

Routine platelet transfusion is avoided because of concern that it may worsen microvascular thrombosis; a low count alone is not an indication. Platelets are reserved exclusively for active, life-threatening internal hemorrhage (e.g., intracranial hemorrhage) or prior to invasive emergency surgery.

Supportive Management of STEC-HUS

Phase-Appropriate Fluid Management : Early isotonic IV hydration during STEC diarrhea may reduce renal injury. Once HUS is established, assess perfusion, urine output and fluid balance; correct hypovolemia, but restrict and tailor fluids in oligo/anuria or overload with nephrology input.

Red Blood Cell Transfusion : Administer packed red blood cells (washed, leukodepleted) cautiously when hemoglobin plummets below 60 to 70 g/L 60\text{ to }70\text{ g/L} 60 to 70 g/L or in the presence of cardiopulmonary compromise.

Renal Replacement Therapy (RRT) : Approximately 50% of children with STEC-HUS require dialysis during the acute phase. Peritoneal dialysis (PD) is preferred in young children; continuous venovenous hemofiltration (CVVH) or hemodialysis is utilized in older children or hypercatabolic states.

Long-Term Prognosis : Acute mortality is < 2 % <2\% < 2% . While > 85 % >85\% > 85% recover normal renal function initially, up to 30% develop long-term chronic sequelae (hypertension, proteinuria, or chronic kidney disease) years later, requiring yearly nephrology surveillance.

Atypical HUS (aHUS / Complement-Mediated HUS)

Accounts for 5% to 10% of cases; carries an ominous prognosis if untreated, with up to 50% progressing to ESRD.

Etiology : Uncontrolled, continuous activation of the alternative complement pathway caused by loss-of-function genetic mutations in complement regulatory proteins ( Factor H [CFH] , Factor I [CFI] , Membrane Cofactor Protein [MCP/CD46] ), gain-of-function mutations in C3 or Factor B , or acquired neutralizing anti-Factor H autoantibodies .

Clinical Presentation : Occurs at any age, typically without a preceding diarrheal prodrome; marked by insidious, recurrent episodes of thrombotic microangiopathy.

Definitive Targeted Therapy : Eculizumab (or Ravulizumab), a humanized monoclonal antibody directed against complement protein C5 , halting the formation of the cytolytic membrane attack complex (MAC, C5b-9). Eculizumab has revolutionized aHUS, inducing complete remission in > 80 % >80\% > 80% . Mandatory meningococcal vaccination and continuous antibiotic prophylaxis are required before initiating therapy.

Hyperkalaemia: Emergency Resuscitation Protocol

Hyperkalaemia is the most lethal electrolyte emergency in pediatric nephrology, disrupting myocardial resting membrane potentials and precipitating fatal ventricular arrhythmias.

Reference Intervals : Children: 3.5 – 5.0 mmol/L 3.5\text{--}5.0\text{ mmol/L} 3.5 – 5.0 mmol/L ; Neonates: 3.5 – 6.0 mmol/L 3.5\text{--}6.0\text{ mmol/L} 3.5 – 6.0 mmol/L .

Emergency Threshold : Severe hyperkalaemia ( K + > 6.5 mmol/L K^+ >6.5\text{ mmol/L} K + > 6.5 mmol/L ) requires urgent treatment and ECG monitoring. Give IV calcium for hyperkalaemic ECG conduction abnormalities; initiate potassium shifting and removal promptly.

Sequential Electrocardiographic (ECG) Changes Normal ECG Peaked T-Waves PR Prolongation / Loss of P Sine Wave / VF

  • R R R
  • / \ / \ / \ /\ /\
  • / \ T / \ /\ / \ / \ / \
  • / \ / \ / \ / \ / \ / \/ \
  • P \_/ \ P \_/ \ / \_---\_ / \ \
  • -+---------------+-------+----------------+--------------+---------------+-------+--------+----+---

Tall, symmetrical, peaked ("tented") T waves with a narrow base (earliest finding; prominent in precordial leads V 2 – V 4 V_2\text{--}V_4 V 2 ​ – V 4 ​ ).

Prolongation of the PR interval , accompanied by progressive flattening and eventual disappearance of the P wave .

Widening of the QRS complex , ST segment depression, and intraventricular conduction delays.

Sine Wave Pattern : The widened QRS complex fuses directly with the peaked T wave, producing a smooth biphasic undulating waveform—the harbinger of imminent cardiac arrest.

Ventricular fibrillation, pulseless electrical activity (PEA), or asystole .

Emergency Pharmacotherapy: RCUK-Based Non-Arrest Protocol and Adjuncts

Step Intervention Pediatric Dose & Route Onset Mechanism of Action

Stabilize Myocardium if ECG Toxicity 10% Calcium Gluconate 0.5 mL/kg 0.5\text{ mL/kg} 0.5 mL/kg ( 50 mg/kg 50\text{ mg/kg} 50 mg/kg , max 30 mL 30\text{ mL} 30 mL ) IV over 5–10 min under continuous ECG 1–3 min (lasts 30–60 min) Antagonizes potassium's membrane depolarizing effect by raising cardiac action potential threshold; does NOT lower serum K + K^+ K +

Step 2: Shift K + K^+ K + into Cells Soluble Insulin + Dextrose Regular insulin 0.1 units/kg 0.1\text{ units/kg} 0.1 units/kg (max 10 units) with 5 mL/kg 5\text{ mL/kg} 5 mL/kg of 10 % 10\% 10% dextrose ( 0.5 g/kg 0.5\text{ g/kg} 0.5 g/kg ; max 250 mL) IV over 30 min, followed by glucose-containing fluid 15–30 min (lasts 2–4 hours) Stimulates Na + / K + \text{Na}^+/\text{K}^+ Na + / K + -ATPase pump to drive potassium into cells; check glucose and potassium every 15 min for 4 hours

Step 2: Shift K + K^+ K + into Cells Nebulized Salbutamol 2.5 mg 2.5\text{ mg} 2.5 mg (if < 25 kg <25\text{ kg} < 25 kg ) or 5.0 mg 5.0\text{ mg} 5.0 mg (if > 25 kg >25\text{ kg} > 25 kg ) via oxygen-driven nebulizer 15–30 min (lasts 2–3 hours) β 2 \beta_2 β 2 ​ -adrenergic stimulation promotes cellular potassium uptake via cyclic AMP activation

Step 2: Shift K + K^+ K + into Cells Sodium Bicarbonate 8.4% 1 to 2 mmol/kg 1\text{ to }2\text{ mmol/kg} 1 to 2 mmol/kg slow IV over 10–20 min 15–30 min Indicated ONLY if severe metabolic acidosis ( p H < 7.15 pH <7.15 p H < 7.15 ); drives H + / K + \text{H}^+/\text{K}^+ H + / K + exchange

Step 3: Eliminate from Body Loop Diuretic (Furosemide) 1 to 2 mg/kg 1\text{ to }2\text{ mg/kg} 1 to 2 mg/kg IV bolus 30–60 min Promotes kaliuresis in renal collecting ducts; effective only if residual renal urine output exists

Step 3: Eliminate from Body Potassium Binders Sodium zirconium cyclosilicate (SZC) or Calcium Polystyrene Sulfonate 2–4 hours Binds potassium in the gastrointestinal tract; SZC contains sodium, so account for sodium load and fluid retention

Step 4: Extracorporeal Removal Renal Replacement Therapy Emergency Hemodialysis, CVVH, or Peritoneal Dialysis Immediate on initiation The definitive therapeutic modality for refractory, anuric, or life-threatening hyperkalaemia

Warning

Calcium Preparation and Context : Calcium chloride contains about three times as much elemental calcium as calcium gluconate and can cause severe extravasation injury. Prefer 10% calcium gluconate for peripheral access. When indicated, 10% calcium chloride ( 0.2 mL/kg 0.2\text{ mL/kg} 0.2 mL/kg , max 10 mL) requires secure access, preferably central. For hyperkalaemic cardiac arrest, follow PALS; RCUK 2025 advises against calcium for paediatric hyperkalaemic cardiac arrest .

Dysnatraemia: Pathophysiology and Correction Guidelines

Sodium disorders reflect imbalances in free body water relative to total body solute. Because the brain cannot rapidly adjust to sudden osmolar shifts, dysnatraemias carry immense neurological vulnerability.

Hyponatraemia (Serum Na + < 135 mmol/L \text{Na}^+ <135\text{ mmol/L} Na + < 135 mmol/L )

Classified by extracellular volume status:

Hypovolaemic Hyponatraemia : Loss of sodium exceeds loss of water (severe gastroenteritis with vomiting/diarrhea, burns, third-spacing, salt-losing congenital adrenal hyperplasia). Urine Na < 20 mmol/L \text{Na} <20\text{ mmol/L} Na < 20 mmol/L indicates extra-renal loss; urine Na > 20 mmol/L \text{Na} >20\text{ mmol/L} Na > 20 mmol/L indicates renal salt wasting.

Euvolaemic Hyponatraemia : Normal extracellular fluid volume with excess free water. Prototype: Syndrome of Inappropriate Antidiuretic Hormone (SIADH) , triggered by meningitis, encephalitis, severe pneumonia, pain, or nausea. Characterized by inappropriately concentrated urine (urine osmolality > 100 mOsm/kg >100\text{ mOsm/kg} > 100 mOsm/kg , urine Na > 30 – 40 mmol/L \text{Na} >30\text{--}40\text{ mmol/L} Na > 30 – 40 mmol/L ) in the presence of plasma hypoosmolality ( < 275 mOsm/kg <275\text{ mOsm/kg} < 275 mOsm/kg ). Treatment is strict fluid restriction .

Hypervolaemic Hyponatraemia : Water retention exceeds sodium retention (congestive heart failure, nephrotic syndrome, acute renal failure). Treatment: Fluid restriction and loop diuretics.

Emergency Management of Acute Symptomatic Hyponatraemic Encephalopathy

When serum sodium plummets rapidly ( < 48 hours <48\text{ hours} < 48 hours ), water moves along an osmotic gradient into astrocytes, generating acute cerebral edema, raised intracranial pressure, projectile vomiting, intractable seizures, tentorial herniation, and coma.

EMERGENCY INTERVENTION :

Infuse Intravenous 3% Hypertonic Saline at 3 to 5 mL/kg 3\text{ to }5\text{ mL/kg} 3 to 5 mL/kg infused over 10 to 15 minutes .

May repeat once or twice if seizures persist, aiming to acutely elevate serum sodium by 3 to 5 mmol/L 3\text{ to }5\text{ mmol/L} 3 to 5 mmol/L . This initial partial correction reduces cerebral edema and may control symptoms. Reassess after each bolus and measure sodium at least hourly during acute correction.

THE CEILING OF CORRECTION (PREVENTING OSMOTIC DEMYELINATION) :

In chronic hyponatraemia ( > 48 hours >48\text{ hours} > 48 hours duration), brain cells adapt by shedding intracellular organic osmolytes (myo-inositol, glutamate, taurine).

If chronic hyponatraemia is corrected too rapidly, water is drawn rapidly out of brain tissue, shrinking oligodendrocytes and triggering Osmotic Demyelination Syndrome (ODS) / Central Pontine Myelinolysis (CPM) .

Clinical features of ODS : Dysarthria, dysphagia, horizontal gaze paralysis, spastic quadriparesis, pseudobulbar palsy, and "locked-in syndrome", typically appearing 2 to 6 days after the rapid correction.

MANDATORY CORRECTION RATE LIMIT : The rate of serum sodium correction in chronic hyponatraemia must NEVER exceed 8 to 10 mmol/L in 24 hours (and ≤ 18 mmol/L \le 18\text{ mmol/L} ≤ 18 mmol/L in 48 hours).

Hypernatraemia (Serum Na + > 145 mmol/L \text{Na}^+ >145\text{ mmol/L} Na + > 145 mmol/L )

Hypernatraemic dehydration represents a catastrophic hyperosmolar state, typically caused by severe viral gastroenteritis with high insensible losses, central/nephrogenic diabetes insipidus, or improper infant formula preparation (adding excess powder or table salt).

Clinical Presentation : Doughy, velvety skin turgor, extreme unquenchable thirst, high-pitched shrill cry, hyperreflexia, hyperthermia, and profound lethargy.

Pathophysiology and Idiogenic Osmoles :

Hypertonicity draws water out of neurons, causing acute brain shrinkage and mechanical traction on delicate bridging dural veins, potentially triggering subdural hematomas or sagittal sinus thrombosis .

Over 24 to 48 hours, brain astrocytes synthesize protective intracellular "idiogenic osmoles" (amino acids, polyols) to pull water back and normalize intracellular brain volume.

THE DANGER OF RAPID CORRECTION: FATAL CEREBRAL EDEMA :

If hypotonic fluids are administered rapidly, extracellular osmolality plummets faster than idiogenic osmoles can be degraded.

Water surges into the brain cells along the osmotic gradient, precipitating malignant cerebral edema, intractable convulsions, brainstem herniation, and death .

SAFE REHYDRATION PROTOCOL :

Assess and treat shock first. Replace the deficit slowly, usually over at least 48 hours ; Na + ≥ 170 mmol/L \text{Na}^+\ge 170\text{ mmol/L} Na + ≥ 170 mmol/L requires specialist care and individualized correction over several days .

Start with 0.9% sodium chloride with 5% glucose for deficit replacement. Reassess sodium and fluid balance frequently; use hypotonic fluid only after expert review of the response.

MANDATORY REDUCTION CEILING : The rate of serum sodium decline must NOT exceed 0.5 mmol/L per hour (or maximum 10 to 12 mmol/L 10\text{ to }12\text{ mmol/L} 10 to 12 mmol/L in 24 hours ).

Monitor serum sodium concentrations every 2 to 4 hours, adjusting infusion rates dynamically to enforce this safe ceiling.